RE: Chief Business Officer11 Aug 2023 13:02
Iain, the LFT was granted EU use for business and retail months before Omicron. The EU market was far bigger than the Uk. The sales did not materialise.
The TT took far far longer than AS led us to believe (with no explanation at the time as to why, and in the end it looks like it was uneconomic as well.
To top this off the test had an antibody in its makeup which i think if memory serves, AVCT never mentioned having previously highlighted the new novel, quick and cheap method of their approach which was to replace antibody derived tests
Further when it was pulled a new test would quickly be launched and it was not.
I am not bothered anymore about this but it does highlight that the AVCT board can be somewhat economical with the truth so when as a for instance AS says, the results thus far show it has therapeutic significance or relevance, what does that ACTUALLY mean?
As a result of factual history, (not made up guesses), I am extremely cautious about putting too much weight on the words that accompany the actual data.
And for my own part I think the SP tends to be, on all stocks, a pretty good precursor to likely events and right now as the trial continues the SP languishes which in turn suggests to me that the market (inc BP) is waiting for the data too, not the hyperbole, before deciding to re-rate the stock.